Transparency Market Research has published a new report on the global dilated cardiomyopathy therapeutics market. As per the report, the global dilated cardiomyopathy therapeutics market is predicted to decline at a CAGR of -7.0% from 2014 to 2020.The report, titled ‘Dilated Cardiomyopathy Therapeutics Market – Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020,’ states that the global market was valued at US$651.0 mn in 2013 and is expected to reach US$328.6 mn by 2020. Factors such as the introduction of gene and stem cell therapies for DCM and the side effects of DCM drugs are expected to restrain the global dilated cardiomyopathy therapeutics market in the years to come.
This 90 page report gives readers a comprehensive overview of the dilated cardiomyopathy therapeutics market. Browse through 5 data tables and 23 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/dilated-cardiomyopathy-market.html
Heart failure is primarily caused by dilated cardiomyopathy (DCM). DCM commonly develops in people aged between 20 years and 60 years. DCM is one of the primary factors, which indicates the need of heart transplantation. Approximately 30% to 40% of people genetically inherit DCM. Factors such as thyroid disorders, diabetes, a viral infection in the heart valve, and alcoholism could cause DCM. As per the Pediatric Cardiomyopathy Registry, dilated cardiomyopathy affects 6 out of 1 million children. DCM is commonly diagnosed in young children, the common diagnosis age being 2 years.
The global dilated cardiomyopathy therapeutics market is segmented on the basis of region and drug class. Some of the commonly used drug classes in DCM treatment are aldosterone antagonists, angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, and beta blockers. In 2013, the angiotensin II receptor blockers (ARBs) segment held the largest share in the global dilated cardiomyopathy therapeutics market. In 2013, the beta blockers segment was the second largest segment in the global dilated cardiomyopathy therapeutics market.
The increasing incidence of congestive heart failure is expected to drive the global dilated cardiomyopathy therapeutics market in the coming few years. DCM accounts for 30% to 40% of congestive heart failure cases every year, reports suggest. Considering the increasing incidence of congestive heart failure, leading players have started initiating many clinical trial studies for DCM. Going forward, a global rise in the number of heart failure cases is expected to increase the demand for effective treatments. This is expected to drive the global dilated cardiomyopathy therapeutics market in the near future. The global market is expected to be hampered by the rising availability of implantable devices and the side effects of DCM drugs.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving dilated cardiomyopathy therapeutics market during 2014 – 2020: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2293
Based on geography, the global dilated cardiomyopathy therapeutics market is divided into Asia Pacific, Europe, North America, and Rest of the World. In 2013, in terms of revenue, North America held a massive share in the global dilated cardiomyopathy therapeutics market due to the increasing acceptance of branded drugs and the increasing incidences of congestive heart failure here.
Some of the key companies operating in the global dilated cardiomyopathy therapeutics market are Array BioPharma, Inc., Celladon Corporation, Janssen Pharmaceuticals, Inc., Novartis International AG, Sanofi S.A., Vericel Corporation, and AstraZeneca plc.
Transparency Market Research
90 State Street,
NY – 12207
USA – Canada Toll Free 866-552-3453